Since the ongoing COVID-19 pandemics requires urgent action, in this work we have conducted a docking screening study of drugs approved worldwide (approximately 6000 compounds, as deposited in the ZINC database ). The goal was to identify potential high affinity blockers of SARS-CoV-2 E channel, available on the pharmaceutical market, to recommend for further pre-clinical investigation.